Eur Rev Med Pharmacol Sci 2018; 22 (18): 6015-6019
DOI: 10.26355/eurrev_201809_15937

Central nervous disease in pediatric patients during acute lymphoblastic leukemia (ALL): a review

M.-W. Jin, S.-M. Xu, Q. An

Department of Pediatrics, Xuzhou Children’s Hospital, Xuzhou, Jiangsu, P.R. China. aiqiangel@yeah.net

Acute lymphoblastic leukemia (ALL) is one of the frequently reported malignancies of childhood age. Earlier it was thought to be a fatal pathological state with no cure, but with advancements in medicine and science, new therapeutic approaches have resulted in better management and cure. However, one of the major hurdles in achieving a complete cure is the relapse of ALL at extra-medullary sites like the central nervous system (CNS). The present review article is focused on recent diagnostic avenues available for the detection of CNS disease during acute lymphoblastic leukemia (ALL) in young patients.

Free PDF Download

To cite this article

M.-W. Jin, S.-M. Xu, Q. An
Central nervous disease in pediatric patients during acute lymphoblastic leukemia (ALL): a review

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 18
Pages: 6015-6019
DOI: 10.26355/eurrev_201809_15937

Keywords Related articles:

  1. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia
  2. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia
  3. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis
  4. Attenuating the abnormally high expression of AEBP1 suppresses the pathogenesis of childhood acute lymphoblastic leukemia via p53-dependent signaling pathway
  5. MiR-410 regulates malignant biological behavior of pediatric acute lymphoblastic leukemia through targeting FKBP5 and Akt signaling pathway